Short course preventive therapy for tuberculosis is successful in HIV-infected patients.

Research output: Contribution to journalArticle

Abstract

Two independent clinical trials are showing that patients with HIV and latent tuberculosis infections may only need two months of treatment to prevent active tuberculosis development. Studies examined the use of rifampin (RIF) and pyrazinamide (PZA), or isoniazid (INH) and pyridoxine. Results show that RIF/PZA, dosed either daily or twice weekly, is as effective in preventing tuberculosis in dually-infected adults, as INH/pyridoxine given for 6-12 months. Data on drug regimens used in preventing tuberculosis in patients with HIV infection are highlighted.

Original languageEnglish (US)
Pages (from-to)2-3
Number of pages2
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Volume10
Issue number3
StatePublished - May 1998
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Short course preventive therapy for tuberculosis is successful in HIV-infected patients.'. Together they form a unique fingerprint.

  • Cite this